Think Alpha-mannosidosis
Early signs — recurrent ear and respiratory infections, hearing loss, coarsening facial features, and developmental delay affecting speech, cognition, or motor skills — are typically managed in isolation across different specialties. Thinking AM means recognizing these as facets of one underlying condition rather than separate problems, even when the overall picture appears mild.
Act Early
Because presentation varies and the early signs are nonspecific, AM is often diagnosed only after years of separate referrals. Once it is suspected, an enzyme assay for acid alpha-mannosidase or MAN2B1 genetic testing can confirm the diagnosis. Acting early means considering AM behind recurrent, multi-system presentations rather than treating each in turn.
Transform Lives
An approved enzyme replacement therapy addresses the non-neurological features of AM — supporting immune function, hearing, and physical capacity — with the strongest gains when treatment starts early. Ongoing multidisciplinary monitoring across ENT, immunology, orthopedics, and neurology shapes long-term outcomes.
.webp)
%20(1).webp)
%20(1).webp)
